Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
APRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.09 - $6.70
Previous CloseN/A
Volume2.88K
Average Volume (3M)20.49K
Market Cap
$11.48M
Enterprise Value-$1.95M
Total Cash (Recent Filing)$65.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 19, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.38
Shares Outstanding5,491,953
10 Day Avg. Volume11,196
30 Day Avg. Volume20,493
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.91
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$20.00Price Target Upside856.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Aprea Therapeutics News
PremiumCompany Announcements
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress
PremiumPre-Earnings
Is APRE a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe company is focused on continued delivery of data across its two precision oncology clinical programs being developed for treatment of solid tumors.
Clinical SafetyEarly clinical safety data for Aprea's molecules is better than other molecules out there, with continuous dosing which is the ideal strategy.
Safety ProfileThe safety profile for ATRN-119 continues to be favorable, which is a departure from other ATRi drugs in development that faced toxicity issues.
Bears Say
EarningsAprea announced 3Q24 results, posting EPS of ($0.64) compared with analyst estimate of ($0.62) and consensus of ($0.74).
Financial PerformanceAprea announced 3Q24 results, posting EPS of ($0.64) compared with analyst estimate of ($0.62) and consensus of ($0.74).
Valuation ImpactChallenges on safety and dosing have negatively impacted the valuations of similar companies like Repare and Zentalis, affecting APRE shares.
---
Ownership Overview
12.36% Insiders
4.13% Mutual Funds
31.39% Other Institutional Investors
48.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $2.09 and its highest was $6.70 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $11.48M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is May 19, 2025 which is in 48 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Mar 25, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.66 by $0.17.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.65.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 5,491,953 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.66. Following the earnings report the stock price went down -3.097%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
---
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
---
APRE Stock 12 Month Forecast
Average Price Target
$20.00
▲(856.94% Upside)
Technical Analysis
Kura Oncology
―
Zai Lab
―
Replimune Group
―
Cyclerion Therapeutics
―
PMV Pharmaceuticals
―
Best Analysts Covering APRE
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-40.33%
reiterated a buy rating 3 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -40.33% per trade.
---